All News
+RCT in #pSjD #Sjogrens #Disease
#Leflunomide + #hydroxychloroquine
Vs #PBO
2nd study to show this - same group
need to know
▶️what pt to use this in
▶️is there diff organ improvements
⬆️#ESSDAI
⬇️RF ⬇️Ig’s
Easy to prescribe
?early, mild dx
#EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
What ‘CAR’ to drive?
#CAR-T buzz was at #EULAR2025
In multiple #rheumatic #diseases
#SLE
#Scleroderma
#Sjogrens
#myositis
Even #axial #SpA
Who - active, not a lot of damage
Which target 🎯
Which priming regiment
What will results be compared to?
Who will pay?
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
APEX study showed significant inhibition of structural damage progression with both dosing regimens (Q4W and Q8W) of GUS (IL-23i) in biologic-naïve pts with active PsA.
Abstract #LB0010
#EULAR2025
@RheumNow https://t.co/QxYAPGB67v
Adela Castro AdelaCastro222 ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis at Risk for Interstitial Lung Disease
A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD).
https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X
Dr. John Cush RheumNow ( View Tweet)
Late-Onset Disease: Different Age, Different Rules?
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related https://t.co/ubVRhhRGxG
Dr. John Cush RheumNow ( View Tweet)
#Enpatoran a #TLRi in Phase2 #SLE #RCT
-previous data + small #cutaneous #lupus study
various doses &PBO approx 25/group
Interesting data - seems to ⬇️#IFN
+ endpoints
👀 for more to come! Safe so far
#EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX
Links:
Janet Pope Janetbirdope ( View Tweet)
Biologic switching in PsA:
-Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once.
-TNFis were the initial therapy.
-IL17i were the first switch in both single-switch and multi-switch scenarios.
-Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR vs #ACR #RA #recommendations
Do you agree that #ERA pts should receive #glucocorticoids
@RheumNow #EULAR2025
@eular_org
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ARIAA study: longer-term data now
High-risk ACPA+ clinically suspect arthralgias
abatacept for 6mo, then stop altogether
Really impressive long-term effect
also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while
#EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
Links:
David Liew drdavidliew ( View Tweet)
Sacroiliac joint involvement in #Psoriatic_arthritis
🔹️681 patients
🔹️Age 45
🔹️31% MRI-positive sacroiliitis
🔹️29% radiographic sacroiliitis
🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis
POS0297
#EULAR2025
@RheumNow https://t.co/gKANc6mNZB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Data from COAST-V study (post hoc)
🔹️Ixekizumab in #axSpA
🔹️Efficacy stratified by CRP level
🔹️Better treatment response in the elevated compared to the normal CRP group
OP0699
#EULAR2025
@RheumNow https://t.co/1mVoly3Gws
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#CAR-T in active #scleroderma #diffuse
open label
@sclerodermaUM presented improvement in
#nailfold #capillary patterns
Suggesting #vascular recovery
Hope is for lungs, skin and survival to improve but
These are ▶️
Early days ?risk
OP0338
#EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk
Janet Pope Janetbirdope ( View Tweet)
Highlights @eular_org #EULAR2025
RCTs + in CTD/RA #ILD w #PPF LB0003
Lots of #CAR-T studies in #SARDs
Lots of bDMARDs in
#SLE
#APS
#IgG4
#SjD
Neurostimulation 👇
⬇️inflammation
⬇️pain
#RA
#fibromyalgia
#EULAR2025 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?
🔹️245 pts
🔹️CRP recorded for past 5y
🔹️sustained high CRP in 40%
🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis
POS0714
#EULAR2025
@RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Management of AAV:
1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction.
2. RTX effective for induction and maintenance, best for relapses.
3.PLEX: in RPGN pts if accesible ⚠️ risk for infection.
4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Pearls on EGPA:
1. GC are mainstay for mild
dz
2. Organ threatening/relapsing➡️CYP (RTX alternative)
3. W/o organ threatening➡️ anti-IL-5/IL-5R.
4. IL5i are less effective for ENT
5. Consider sx for nasal polyps.
#EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Links:
Adela Castro AdelaCastro222 ( View Tweet)
